JP2002523506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002523506A5 JP2002523506A5 JP2000567530A JP2000567530A JP2002523506A5 JP 2002523506 A5 JP2002523506 A5 JP 2002523506A5 JP 2000567530 A JP2000567530 A JP 2000567530A JP 2000567530 A JP2000567530 A JP 2000567530A JP 2002523506 A5 JP2002523506 A5 JP 2002523506A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- hydrogen
- disorder
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 30
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- -1 arylsulfoxyl Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GSMBZPFAFVMZKF-UHFFFAOYSA-N 1-(5-chloropyrrolo[2,3-f]quinolin-1-yl)propan-2-amine Chemical compound N1=CC=CC2=C3N(CC(N)C)C=CC3=CC(Cl)=C21 GSMBZPFAFVMZKF-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- NGJPDQGQHNZKRA-UHFFFAOYSA-N N1(C=CC=2C1=C1C=CC=NC1=CC2)NC(C)C Chemical compound N1(C=CC=2C1=C1C=CC=NC1=CC2)NC(C)C NGJPDQGQHNZKRA-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9819019.2A GB9819019D0 (en) | 1998-09-01 | 1998-09-01 | Chemical compounds II |
| GB9819019.2 | 1998-09-01 | ||
| PCT/GB1999/002887 WO2000012502A1 (en) | 1998-09-01 | 1999-09-01 | Pyrroloquinolines for treatment of obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002523506A JP2002523506A (ja) | 2002-07-30 |
| JP2002523506A5 true JP2002523506A5 (enExample) | 2006-11-02 |
Family
ID=10838154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000567530A Pending JP2002523506A (ja) | 1998-09-01 | 1999-09-01 | 肥満の処置のためのピロロキノリン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6365598B1 (enExample) |
| EP (1) | EP1109809B1 (enExample) |
| JP (1) | JP2002523506A (enExample) |
| AT (1) | ATE282613T1 (enExample) |
| AU (1) | AU5637799A (enExample) |
| CA (1) | CA2341986A1 (enExample) |
| DE (1) | DE69922024T2 (enExample) |
| DK (1) | DK1109809T3 (enExample) |
| ES (1) | ES2232168T3 (enExample) |
| GB (1) | GB9819019D0 (enExample) |
| PT (1) | PT1109809E (enExample) |
| WO (1) | WO2000012502A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| GB9918965D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| DE60139021D1 (de) | 2000-11-20 | 2009-07-30 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors |
| US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| US7214690B2 (en) | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
| EP1513831B1 (en) | 2002-06-19 | 2010-01-06 | Biovitrum AB (publ) | Novel compounds, their use and preparation |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| CA2495192A1 (en) * | 2002-08-30 | 2004-03-11 | Alcon, Inc. | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| AP2007004144A0 (en) | 2005-03-31 | 2007-08-31 | Pfizer Prod Inc | Cyclopentapyridine and tetrahydroquinoline derivatives |
| WO2006138347A2 (en) | 2005-06-17 | 2006-12-28 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| WO2007053353A2 (en) * | 2005-10-28 | 2007-05-10 | Wyeth | Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| EP1991531A1 (en) * | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
| WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
| ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| KR101062376B1 (ko) | 2008-04-10 | 2011-09-06 | 한국화학연구원 | 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물 |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| WO2015012704A1 (en) * | 2013-07-25 | 2015-01-29 | Uniwersytet Jagielloński | Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| TW270114B (enExample) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| TW403738B (en) * | 1994-08-12 | 2000-09-01 | Hoffmann La Roche | Tricyclic pyrazole derivatives |
| AU5343298A (en) | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
| AU727654B2 (en) * | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
-
1998
- 1998-09-01 GB GBGB9819019.2A patent/GB9819019D0/en not_active Ceased
-
1999
- 1999-09-01 AU AU56377/99A patent/AU5637799A/en not_active Abandoned
- 1999-09-01 WO PCT/GB1999/002887 patent/WO2000012502A1/en not_active Ceased
- 1999-09-01 CA CA002341986A patent/CA2341986A1/en not_active Abandoned
- 1999-09-01 DE DE69922024T patent/DE69922024T2/de not_active Expired - Fee Related
- 1999-09-01 PT PT99943093T patent/PT1109809E/pt unknown
- 1999-09-01 DK DK99943093T patent/DK1109809T3/da active
- 1999-09-01 AT AT99943093T patent/ATE282613T1/de not_active IP Right Cessation
- 1999-09-01 EP EP99943093A patent/EP1109809B1/en not_active Expired - Lifetime
- 1999-09-01 JP JP2000567530A patent/JP2002523506A/ja active Pending
- 1999-09-01 ES ES99943093T patent/ES2232168T3/es not_active Expired - Lifetime
- 1999-09-01 US US09/786,159 patent/US6365598B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002523506A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2002523491A5 (enExample) | ||
| JP2003507367A5 (enExample) | ||
| JP2003507366A5 (enExample) | ||
| JP2002525280A5 (enExample) | ||
| JP2002535408A5 (enExample) | ||
| CA2422698A1 (en) | Indoline derivatives and their use as 5-ht2 receptor ligands | |
| JP2007508361A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2004527467A5 (enExample) | ||
| JP3828422B2 (ja) | 新規アザインドリル誘導体 | |
| JP2004505085A5 (enExample) | ||
| JP2004532823A5 (enExample) | ||
| RU2001108570A (ru) | Пирролоиндолы, пиридиноиндолы и азепиноиндолы в качестве агонистов 5-нт2с | |
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| WO2002059129A3 (en) | Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists | |
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| RU2004133068A (ru) | Модуляторы 5нт2с рецептора | |
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| RU2006116885A (ru) | Производные n-фенил(пиперидин-2-ил)метил-бензамида, способ получения указанных соединений и их применение в терапии | |
| WO2005080343A3 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
| KR950011407A (ko) | 트리사이클릭 1-아미노에틸피롤 유도체 | |
| JP2009542613A5 (enExample) |